BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
Recruiting
N/A
Interventional Study
Depressive Symptoms
Urinary Incontinence
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 22 – 60
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- BTL Industries Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy, singleton infant 2-60 months before enrollment in the study and are aged 22 years and older, but under the age of 60 years. The main question it aims to answer is: Does th…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Delivery of a healthy, singleton infant 2-60 months before enrollment in the study
* Current involvement in caregiving or regular contact with the child in question
* Patient Health Questionnaire-9 (PHQ-9) pre-treatment score of ≥ 5
* Age ≥ 22, but ≤ 60 years
* Ability to dete…
Contacts
No contact information available.